• 25 Jul 25
 

Wells Fargo Bank NA - Notice of Amended and Restated Pricing Supplement


 
RNS Number : 6657S
Wells Fargo Bank N.A.
25 July 2025
 

25 July 2025

NOTICE OF AMENDED AND RESTATED PRICING SUPPLEMENT

WELLS FARGO BANK, NATIONAL ASSOCIATION

U.S.$10,000,000,000

Euro Medium Term Note Programme

 

HKD 380,000,000 3.90 per cent. Notes due 28 April 2028 (Series 16, Tranche 2; ISIN: XS3060175869; Common Code: 306017586)  (the "Notes")

 

This notice ("Notice") is supplemental to, and should be construed together with the Information Memonrandum dated 18 September 2023 relating to the U.S.$10,000,000 Euro Medium Term Note Programme of Wells Fargo Bank, National Association and the pricing supplement dated 11 June 2025 relating to the Notes (the "Original Pricing Supplement").

The Issuer hereby gives notice to all Noteholders that the Original Pricing Supplement has been amended and restated (the "Amended and Restated Pricing Supplement") with effect from 24 July 2025.

Specifically, for the purpose of correcting a manifest error, the item "Issue Price" in paragraph 5 contained in "Part A - Contractual Terms" of the Original Pricing Supplement has been deleted in its entirety and replaced with the following:

"5.

Issue Price:

101.8553854 per cent. of the Aggregate Nominal Amount of this Tranche plus accrued interest from and including the Interest Commencement Date"

Terms defined in the Amended and Restated Pricing Supplement have the same meaning when used in this Notice.

To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/6657S_1-2025-7-25.pdf

WELLS FARGO BANK, NATIONAL ASSOCIATION

For further information, please contact

Sandra Galvis

Senior Lead Counsel & Executive Director

Wells Fargo & Company

sandra.j.galvis@wellsfargo.com

 

 

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Amended and Restated Pricing Supplement and/or the information memorandum dated 18 September 2023 relating to the above-mentioned programme ( the "Information Memorandum") may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Amended and Restated Pricing Supplement and/or the Information Memorandum) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Amended and Restated Pricing Supplement and/or the Information Memorandum is not addressed. Prior to relying on the information contained in the Amended and Restated Pricing Supplement and/or the Information Memorandum you must ascertain from the Amended and Restated Pricing Supplement and/or the Information Memorandum whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCPPUPGMUPAGCA

Research Tree RNS Article

To continue viewing this RNS article, please advise if you are one of the following:

Return to News Summary